Keytruda Combination Therapy Cuts Recurrence/Death by 49% in 5-Year Data
MRK sits 53% above its 52-week low of $75.4.
Summary
Merck announced highly positive five-year data for its Intismeran + Keytruda combination therapy, showing a 49% reduction in recurrence or death and a 59% reduction in distant metastasis or death compared to Keytruda alone. This robust long-term clinical data significantly strengthens Merck's leading oncology franchise, building on recent positive pipeline developments including the acquisition of Terns Pharmaceuticals and strong results for its PCSK9 inhibitor. These results are critical for maintaining Keytruda's market dominance and driving future revenue growth.
At the time of this announcement, MRK was trading at $115.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $284.4B. The 52-week trading range was $75.40 to $125.14. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.